Histone deacetylase inhibitor

Histone deacetylase inhibitors (HDAC inhibitors or HDIs) are a class of compounds that interfere with the function of histone deacetylase (HDAC), an enzyme involved in the removal of acetyl groups from the lysine residues on histone proteins. By inhibiting HDAC, these compounds increase the level of acetylation of histones, leading to an open chromatin structure and an increase in gene expression. This mechanism of action has implications in cancer therapy, neurodegenerative diseases, and beyond.

Mechanism of Action

HDAC inhibitors work by blocking the activity of histone deacetylase enzymes. There are 18 known HDACs, which are classified into four classes based on their homology to yeast HDACs. Class I, II, and IV are zinc-dependent enzymes, while Class III enzymes require NAD+ for their activity. HDAC inhibitors can be broad-spectrum, targeting multiple HDACs, or selective, targeting a specific subset.

By inhibiting these enzymes, HDAC inhibitors prevent the deacetylation of histones, leading to an accumulation of acetylated histones. This hyperacetylation of histones causes the chromatin structure to become more open or relaxed, facilitating access of transcription factors to DNA and resulting in an increase in gene expression. Some genes that are upregulated in response to HDAC inhibition are involved in cell cycle arrest, apoptosis, and differentiation, which can suppress tumor growth and proliferation.

Clinical Applications

Cancer

HDAC inhibitors have shown promise in the treatment of various cancers. They can induce cell cycle arrest, apoptosis, and differentiation in cancer cells. Several HDAC inhibitors, such as Vorinostat (SAHA) and Romidepsin, have been approved by the FDA for the treatment of certain types of cancer, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma.

Neurodegenerative Diseases

Research suggests that HDAC inhibitors may also have therapeutic potential in neurodegenerative diseases such as Huntington's disease, Parkinson's disease, and Alzheimer's disease. These compounds can promote neuronal survival and plasticity, and reduce neuroinflammation.

Other Diseases

HDAC inhibitors are being explored for their potential in treating other conditions, including autoimmune diseases, HIV infection, and cardiac hypertrophy. Their ability to modulate gene expression makes them a versatile tool in disease research and therapy.

Types of HDAC Inhibitors

HDAC inhibitors are categorized into several classes based on their chemical structure:

• Hydroxamic acids (e.g., Vorinostat, Trichostatin A)
• Cyclic peptides (e.g., Romidepsin)
• Aliphatic acids (e.g., Valproic acid)
• Benzamides (e.g., Entinostat)

Safety and Side Effects

While HDAC inhibitors offer therapeutic potential, they are not without side effects. Common adverse effects include fatigue, nausea, vomiting, diarrhea, and thrombocytopenia. More serious side effects can include cardiac arrhythmias and prolonged QT interval. The safety profile of HDAC inhibitors continues to be evaluated in clinical trials.

Future Directions

Research into HDAC inhibitors is ongoing, with efforts focused on understanding their mechanisms of action, discovering new therapeutic targets, and developing more selective and potent inhibitors. The role of HDAC inhibitors in combination therapies, particularly in cancer treatment, is also an area of active investigation.

See Also

• Epigenetics
• Histone acetylation
• Cancer therapy
• Neurodegenerative disease

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian